Quarterly ResultMay 13, 2026, 04:47 PM
Harvard Apparatus Regenerative Technology Q1 Revenue Up; Going Concern Doubt
AI Summary
Harvard Apparatus Regenerative Technology reported Q1 2026 product revenue of $226K, a significant increase from $45K in Q1 2025, while net loss slightly improved to $(1.601)M. However, the company's cash and cash equivalents drastically fell to $419K, and it explicitly stated substantial doubt about its ability to continue as a going concern. The company requires additional financing to fund operations beyond the second quarter of 2026.
Key Highlights
- Substantial doubt about the Company's ability to continue as a going concern.
- Cash and cash equivalents decreased to $419K as of March 31, 2026, from $1.352M.
- Company needs additional financing to fund operations beyond Q2 2026.
- Product revenue increased to $226K for Q1 2026, up from $45K in Q1 2025.
- Net loss was $(1.601)M for Q1 2026, a slight improvement from $(1.659)M.
- Net cash used in operating activities increased to $(937)K from $(758)K.
- Total stockholders' equity declined to $92K from $1.057M at Dec 31, 2025.
- Accumulated deficit reached approximately $108.2M as of March 31, 2026.